Document is current

Article History

Received: 25 October 2018

Accepted: 4 January 2019

First Online: 22 January 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: E. Choy reports non-financial support from Novartis during the preparation of this manuscript and grants and personal fees outside of the submitted work from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, BMS, Boehringer Ingelheim, Celgene, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmacuetical, GSK, Hospira, ISIS, Jazz Pharmaceuticals, Janssen, MedImmune, Merrimack Pharmaceutical, MSD, Napp, Novimmune, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi-Aventis, Synovate, Tonix and UCB. X. Baraliakos reports non-financial support from Novartis during the preparation of this manuscript and grants and personal fees from AbbVie, Merck, Pfizer, UCB, Novartis and Chugai. F. Behrens reports non-financial support from Novartis during the preparation of this manuscript and grants and personal fees from AbbVie, Pfizer, Merck Sharp & Dohme, UCB, Celgene, Sandoz, Boehringer, Novartis, Chugai and Janssen. S. D’Angelo reports non-financial support from Novartis during the preparation of this manuscript and grants and personal fees from Abbvie, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Pfizer and UCB. K. de Vlam reports non-financial support from Novartis during the preparation of this manuscript. B.W. Kirkham reports non-financial support from Novartis during the preparation of this manuscript and, outside the submitted work, grants from AbbVie, grants and personal fees from Novartis, Eli Lilly and Roche, and personal fees from Abbott, BMS, Chugai, MSD, Pfizer and UCB. M. Østergaard reports non-financial support from Novartis, during the preparation of this manuscript, and, outside the submitted work, personal fees from Boehringer Ingelheim, grants and personal fees from Celgene, Merck and Novartis, grants from Centocor and personal fees from Pfizer, Eli-Lilly, Roche, UCB, Abbvie, BMS, Hospira, Orion and Regeneron. G.A. Schett reports non-financial support from Novartis, during the preparation of this manuscript. M. Rissler is an employee of Novartis. K. Chaouche-Teyara is an employee and shareholder of Novartis. C. Perella is an employee and shareholder of Novartis.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.